Wilmington Savings Fund Society’s Medicus Pharma MDCX Stock Holding History

Wilmington Savings Fund Society’s Portfolio MDCX Stock Details MDCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.4K	Sell	25,622 -25,622	-50%	-$9.07K	﹤0.01%	1174
2026 Q1	$23.5K	Hold	51,244	–	–	﹤0.01%	1034
2025 Q4	$78.4K	Buy	51,244 +25,622	+100%	+$54.9K	﹤0.01%	793
2025 Q3	$59.3K	Buy	+25,622	New	+$64.3K	﹤0.01%	859

Other funds holding MDCX

ICP

Interchange Capital Partners Pittsburgh, Pennsylvania $532M AUM 26.57% 1-Year Est. Return

SIAP

Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

MCM

Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return

Wilmington Savings Fund Society's MDCX Position: Q2 2026 in Review

Wilmington Savings Fund Society reduced its Medicus Pharma (MDCX) stake by 50% in Q2 2026, selling an estimated $9.07K and leaving 25,622 shares worth $11.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1174.

Wilmington Savings Fund Society first reported a position in MDCX in Q3 2025 and has held it in 4 quarters since. The position peaked at $78.4K in Q4 2025. 6 funds tracked by Wall St. Rank hold MDCX as of Q2 2026.

Wilmington Savings Fund Society held 25,622 shares of Medicus Pharma worth $11.4K as of Q2 2026.
Wilmington Savings Fund Society sold 25,622 Medicus Pharma shares in Q2 2026, an estimated $9.07K.
Medicus Pharma made up ﹤0.01% of Wilmington Savings Fund Society's portfolio in Q2 2026, its #1174 holding.
Wilmington Savings Fund Society first reported a position in Medicus Pharma in Q3 2025 and has held it in 4 quarters since.
Wilmington Savings Fund Society's Medicus Pharma position peaked at $78.4K in Q4 2025.
6 funds tracked by Wall St. Rank held Medicus Pharma as of Q2 2026.

Based on Wilmington Savings Fund Society's 13F filing for Q2 2026, filed 28 Jul 2026.